骨髓瘤患者继发性白血病多年前即可检出干细胞突变
该研究纳入多发性骨髓瘤后发生治疗相关急性髓系白血病或骨髓增生异常综合征(t-AML/t-MDS)的患者,分析其次级疾病发病前数年采集的干细胞与祖细胞。研究发现高表达CD123的异常干细胞在白血病发病前即可检出,超深度测序显示以TP53突变为主的突变造血干细胞(HSC)克隆在白血病发病时成为优势群体,提示HSC可长期作为白血病起始细胞的储库。
要点
- 骨髓瘤患者t-AML/t-MDS发病前数年即可检出高CD123表达的异常干细胞。
- 超深度测序揭示发病前已存在以TP53突变为主要特征的突变HSC克隆。
- 该突变HSC克隆在白血病发病时成为优势群体,提示HSC是白血病起始细胞储库。
核心结论
- 造血干细胞可在髓系白血病发病多年前作为白血病起始细胞的储库。
研究设计与样本
- 研究纳入多发性骨髓瘤后发生t-AML/t-MDS的患者,分析其次级疾病发病前数年采集的干细胞与祖细胞。
主要发现
- 高CD123表达的异常干细胞在明显白血病发病前即可被检出。
- 严格分选后靶向测序达到超深度功能测序深度,检出预先存在的突变HSC克隆,主要以TP53突变为特征。
- 上述突变HSC克隆在白血病发病时成为优势群体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapy-related acute myeloid leukemia and myelodysplastic syndromes (t-AML/t-MDS) are secondary hematologic malignancies associated with poor prognosis, warranting insights into their predisposing conditions and cells of origin. We identified patients with myeloma who developed t-AML/t-MDS and analyzed their stem and progenitor cells collected years before the onset of secondary disease. We demonstrate that aberrant stem cells with high CD123 expression can be detected long before the onset of overt leukemia. Rigorous sorting, followed by targeted sequencing, resulted in ultradeep functional depth of sequencing and revealed preexisting mutant hematopoietic stem cell (HSC) clones, mainly harboring TP53 mutations, that became the dominant population at the time of leukemic presentation. Taken together, these data show that HSCs can act as reservoirs for leukemia-initiating cells many years before the onset of myeloid leukemia.
引用
- Sridharan A, Schinke CD, Georgiev G, et al. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Adv. 2019. PMID: 31805192. doi:10.1182/bloodadvances.2019000731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。